ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2019
The Serogroup B Meningococcal Vaccine Bexsero Elicits Antibodies to Neisseria gonorrhoeae.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06446752 (A Phase 3 Randomized, Observer-Blind, Placebo-Controlled Study to Assess Efficacy of Meningococcal Group B), which is not on this map. Cited by 97 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3 Randomized, Observer-Blind, Placebo-Controlled Study to Assess Efficacy of Meningococcal Group B (rMenB+OMV NZ (Bexsero)) in Preventing Gonococcal Infection Among South African Cis-Gender Women
Who cites it
97 citing papers in PubMed, 3 syntheses or guidelines pooled it, 171 citations in OpenAlex.
- Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis.The Journal of infectious diseases · 2025Pooled it
- A systematic review to identify research gaps in studies modeling MenB vaccinations against Neisseria infections.PloS one · 2025Pooled it
- Epidemiology of gonorrhoea: systematic review, meta-analyses, and meta-regressions, World Health Organization European Region, 1949 to 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Pooled it
- Profiling IgG and IgA antibody responses during vaccination and infection in a high-risk gonorrhoea population.Nature communications · 2024Trial
- Trial
- Comet Assay for Genotoxicity Evaluation of Salmonella Outer Membrane Vesicles.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Article
- Preclinical Evaluation of Novel ConservedVaccines · 2026Article
- A Multidesign Study of 4CMenB Vaccine Effectiveness and Impact on Meningococcal Carriage and Gonorrhea in Northern Territory Adolescents and Young People.Open forum infectious diseases · 2026Article
- Defining the Efficacy of Meningococcal B Vaccines Against Gonococcal Acquisition: The Current Landscape.Journal of the International AIDS Society · 2026Review
- Potential Use of Neisseria meningitidis Serogroup B Vaccines to Prevent Neisseria gonorrhoeae Infection: Epidemiological Considerations.Journal of the International AIDS Society · 2026Review
- Efficacy of the serogroup BBMJ open · 2026Article
- Efficacy of the meningococcal vaccine against Neisseria gonorrhoeae: a randomised clinical trial (MenGO).NPJ vaccines · 2026Article
- Gonococcal outer membrane vesicle vaccines: bacterial population biology, clinical trials, immune profiling, and vaccine design.NPJ vaccines · 2026Review
- Review
- Discovery and characterization of an anti-Frontiers in microbiology · 2026Article
- Extracellular vesicles in chronic wound therapy: engineering strategies and advanced delivery systems for enhanced regeneration.Materials today. Bio · 2025Review
- Effectiveness of the four-component protein-based meningococcal vaccine againstCanada communicable disease report = Releve des maladies transmissibles au Canada · 2025Article
- A novel GMMA-based gonococcal vaccine demonstrates functional immune responses in mice.NPJ vaccines · 2025Article
- Meningococcal vaccine 4CMenB elicits a robust cellular immune response that targets but is not consistently protective againstmSphere · 2025Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeisseria gonorrhoeae and Neisseria meningitidis are closely-related bacteria that cause a significant global burden of disease. Control of gonorrhoea is becoming increasingly difficult, due to widespread antibiotic resistance. While vaccines are routinely used for N. meningitidis, no vaccine is available for N. gonorrhoeae. Recently, the outer membrane vesicle (OMV) meningococcal B vaccine, MeNZB, was reported to be associated with reduced rates of gonorrhoea following a mass vaccination campaign in New Zealand. To probe the basis for this protection, we assessed the cross-reactivity to N. gonorrhoeae of serum raised to the meningococcal vaccine Bexsero, which contains the MeNZB OMV component plus 3 recombinant antigens (Neisseria adhesin A, factor H binding protein [fHbp]-GNA2091, and Neisserial heparin binding antigen [NHBA]-GNA1030).
methodsA bioinformatic analysis was performed to assess the similarity of MeNZB OMV and Bexsero antigens to gonococcal proteins. Rabbits were immunized with the OMV component or the 3 recombinant antigens of Bexsero, and Western blots and enzyme-linked immunosorbent assays were used to assess the generation of antibodies recognizing N. gonorrhoeae. Serum from humans immunized with Bexsero was investigated to assess the nature of the anti-gonococcal response.
resultsThere is a high level of sequence identity between MeNZB OMV and Bexsero OMV antigens, and between the antigens and gonococcal proteins. NHBA is the only Bexsero recombinant antigen that is conserved and surfaced exposed in N. gonorrhoeae. Bexsero induces antibodies in humans that recognize gonococcal proteins.
conclusionsThe anti-gonococcal antibodies induced by MeNZB-like OMV proteins could explain the previously-seen decrease in gonorrhoea following MeNZB vaccination. The high level of human anti-gonococcal NHBA antibodies generated by Bexsero vaccination may provide additional cross-protection against gonorrhoea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.